Evaluation of the effect of milk casein on the pharmacokinetics of rutin

Abstract

Rutin, often referred to as vitamin P, possesses numerous pharmaceutical applications, yet its market availability is restricted due to poor bioavailability. Recent interest has focused on exploiting rutin's therapeutic potential, prompting efforts to enhance its bioavailability. This study aimed to enhance the bioavailability of rutin by formulating tablet dosage forms using cow milk casein as a matrix-forming agent. Tablet formulations containing rutin and milk casein were prepared, and their physicochemical properties were evaluated through in vitro tests, including hardness, friability, and dissolution. Pharmacokinetic studies were conducted using Wistar rat models, analyzing plasma drug concentrations and urine excretion. Stability studies were also performed to assess the tablets' shelf life under various conditions. The results of the study revealed that the incorporation of milk casein significantly improved the bioavailability of rutin, both in vitro and in vivo. Physicochemical evaluations demonstrated satisfactory tablet properties, while pharmacokinetic studies indicated enhanced plasma drug concentrations and reduced urine excretion of rutin with milk casein formulations. Stability studies further supported the suitability of the formulated tablets for long-term storage. In conclusion, milk casein proved effective as a matrix-forming agent for improving the bioavailability of rutin. The formulated tablets exhibited favorable physicochemical properties and enhanced drug absorption characteristics, suggesting the potential utility of milk casein in enhancing the therapeutic efficacy of rutin formulations.